GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo GT Biopharma Inc. (GTBP), a targeted immunotherapies company with close to market treatments for Central Nervous System (CNS) diseases (neurology and pain), will hold a conference call, hosted by www.biotechstocks.com, to discuss advancements made with
Complete Reading

GT Biopharma (OXISD) Announces Development Plan For Non-Opioid Neuropathic Pain Treatment “PainBrake” GT Biopharma Inc. announced today that it has made the required payment to license and develop PainBrake, a non-opioid pain medication, to Accu-Break Pharmaceuticals Inc. The payment allows GT Biopharma (OTCQB: OXISD) to begin the clinical development process and the filing of a
Complete Reading

GT Biopharma Inc. (OXIS) Announces Corporate Update Conference Call PRESS RELEASE GT Biopharma OXIS  Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo GT Biopharma Inc. (OTCQB:OXIS and Euronext Paris OXI.PA), a targeted immunotherapies company with incoming close to market treatments (GTP acquisition) for Central Nervous System diseases (nurology
Complete Reading

Marlin Gold Ships a Quarterly Record of 18,875 Ounces Gold in 1Q17 and Intersects 3.45 g/t Gold Over 7.00 Meters at La Trinidad   BUZ INVESTORS Marlin Gold Ships a Quarterly Record   — Marlin Gold Mining Ltd. (TSX-V: MLN) (“Marlin” or the “Company”)  is pleased to provide an operating update from its wholly owned La
Complete Reading

Alexandria Minerals Intersects Visible Gold-Bearing Veins with up to 30.52 g/t Gold over 2.65 meters at Orenada Toronto, Ontario, February 1, 2017 – Alexandria Minerals Corporation (TSX-V: AZX; Frankfurt: A9D) (“AZX” or the “Company”) is pleased to report the first results received from its current drill program at Orenada Zone 4 in Val d’Or, Quebec.
Complete Reading

Create Account



Log In Your Account



Dash_En